West Pharmaceutical Services (WST) Retained Earnings (2009 - 2026)

West Pharmaceutical Services (WST) has reported Retained Earnings for 18 consecutive years, with $4.6 billion the latest figure, recorded in Q2 2026.

• Quarterly Retained Earnings rose 11.71% year-over-year to $4.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.6 billion (up 11.71% YoY) and the FY2025 annual result came in at $4.4 billion, up 10.57% from the prior year.
• Retained Earnings advanced to $4.6 billion in Q2 2026 per WST's latest filing, from $4.5 billion in the prior quarter.
• Over the last five years, Retained Earnings for WST reached as high as $4.6 billion in Q2 2026 and fell as low as $2.6 billion in Q1 2022.
• A 5-year average of $3.6 billion and a median of $3.7 billion in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings surged 31.83% — and 2025, when it climbed 10.51%.
• Year by year, Retained Earnings stood at $3.0 billion in 2022, then gained by 17.93% to $3.5 billion in 2023, then increased by 12.29% to $4.0 billion in 2024, then advanced by 10.57% to $4.4 billion in 2025, then gained by 5.7% to $4.6 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $4.6 billion, $4.5 billion, and $4.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.